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patients treated with HF, respectively (p=0.154). Grade ≥ 2 late 
genitourinary (GU) toxicity was experienced by 41% and 43% of 
patients treated with SF and HF, respectively (p=0.532). 
From 3 months after RC, only 2% of patients experienced a grade 3 
late GI toxicity in the SF arm versus 1% in the HF arm (p=0.337). Grade 
4 late GI toxicity was reported in 1 patient in the SF arm versus 4 
patients in the HF arm (p=0.373). Late GU grade 3 toxicity was 
reported by 9% and 14% in the SF- and HF arm, respectively (p=123). 
No grade 4 late GU toxicity was reported in the SF arm versus 1 
patient in the HF arm. 
A multivariable analysis evaluating the effect of age, PSA, Gleason-
score, T-stage, use of hormonal therapy, previous TURP, smoking and 
the presence of acute GI/GU toxicity showed that only the presence 
of acute toxicity significantly increased the risk of developing late GI 
toxicity (p=0.000) . For the late GU toxicity, the age >70 (p=0.001), 
the presence of acute GU toxicity (p=0.000) and smoking (p=0.046) 
were significant factors increasing the risk of developing late GU 
toxicity.  
Conclusions: Our initial results on late toxicity, after a median follow-
up of 27 months, show that the hypofractionated treatment is well 
tolerated. No significant differences in late GI and GU toxicity were 
observed compared to the standard fractionation arm. The presence 
of acute GI and GU toxicity were significant prognostic factors for late 
toxicity. Age and smoking were significant prognostic factors for late 
GU toxicity as well.  
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Purpose/Objective: Moderate dose escalation and hypofractionation 
(HYPO) have a possible role in the postprostatectomy (POSTOP) 
setting, both adjuvant (ADV) and salvage (SALV). This analysis focused 
on possible clinical and physico-dosimetric predictors of most severe 
(Grade ≥3) genitourinary toxicity (GU TOX) after POSTOP RT for 
prostate cancer (PCa). 
Materials and Methods: A cohort of 1176 consecutive patients (pts) 
was submitted to POSTOP ADV (n=804) or SALV (n=372) RT between 
1993 and 2010 in a single Institution with conventionally fractionated 
(CF, 1.8 Gy/fraction, fr) non conformal (NC, n=169), 3DCRT (n=657) or 
IMRT (n=103) technique, or moderately HYPO (median 2.50 Gy/fr) 
helical Tomotherapy (n=247). The whole-pelvis (WP) was irradiated in 
345 pts. The median dose to the prostatic bed and WP was 70.2 Gy 
and 50.4 Gy, respectively, in the CF group. For the HYPO group, 3 
cohorts were identified: 116 treated at a median of 65.8 Gy (2.35 Gy x 
28), 76 at 71.4 Gy (2.5-2.6 x 28) and 49 at 58 Gy in 20 Gy. In the HYPO 
group the most common WPRT schedule was 51.8 Gy/28 fr. Total 
doses were also converted in biological equivalent doses (BED) 
following the linear quadratic model (LQ) taking a/b = 3 or 5. We 
focused on Grade ≥3 toxicity, retrospectively graded according to 
CTCAE v 4.0. 
Results: After a median follow-up of 95 months (60 for HYPO), 121 pts 
experienced Grade 3 late TOX (57 urethral or bladder neck strictures 
requiring interventions ± 49 severe urinary incontinence 
onset/worsened after RT ± 25 gross haematuria) and 5 underwent 
cystectomy (Grade 4). Patients were grouped in 3 classes, according 
to the dose/fr received: A=1.8-2.0 Gy, B=2.3-2.4 Gy, C=2.5-2.9 Gy. At 
univariate analysis, the 5-year risk of TOX G≥3 was predicted by 
fractionation (7% vs 15% vs 21% for groups A, B and C, respectively, 
p<0.0001), acute Grade ≥2 TOX (18% vs 8%, p=0.0001) and use of anti-
hypertensives (HYPERT, 12% vs 7%, p=0.04). At multivariate analysis 
(MVA) the only predictive covariate of Grade≥3 TOX in the overall 
population was acute Grade ≥2 TOX (HR 2.49, p=0.0002), while 
fractionation (p=0.06) and HYPERT (p=0.09) were found to be of only 
borderline significance. In the HYPO subgroup, the only significant 
variable at MVA was HYPERT (HR 8.15, p=0.008). Overall, BED was not 
predictive. 
Conclusions: This is the largest data set focusing on the impact of 
different doses and fractionations on severe GU toxicity after POSTOP 
RT for PCa, suggesting the existence of an important 'consequential' 
component for the onset of severe late GU toxicity, and an important 
role of HYPERT. Moreover, the impact of an increased daily dose 
effect (from 1.8-2 to 2.3-2.9 Gy/fr) is completely inconsistent with 
the linear-quadratic model, suggesting that HYPO exacerbates severe 
GU TOX far more than would be expected from BED calculation. This 
effect may suggest an increased incomplete repair effect of the 
urothelium, possibly enhanced by the previous surgery. 
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Based on prospective trials, stereotacticbody radiotherapy (SBRT) has 
become the standard of care for early stage non-small cell lung cancer 
(NSCLC): high accuracy of the whole radiotherapy work-flow allowed 
safe delivery of escalated irradiation doses, which significantly 
improved local tumor control and overall survival compared to 
conventionally fractionated radiotherapy. Local surgical treatment of 
oligo-metastatic lung and / or liver lesions has shown promising long 
term overall survival with cure in a proportion of the patients and 
these results were the rational for exploring the role of SBRT in the 
setting of pulmonary metastases. Until today, several prospective 
trials have investigated safety and efficacy of SBRT in this metastatic 
setting. The majority of the studies limited the number of treated 
pulmonary lesions or lesions anywhere in the body to 3 – 5 and SBRT 
irradiation doses were similar to experiences in SBRT for stage I 
NSCLC, mostly higher than 100Gy BED. However, lesions were rather 
small in the majority of the studies and risk-adapted fractionation 
with larger number of treatment fractions and lower total doses are 
recommended in the situation of multiple large-volume disease. 
Integration of SBRT into systemic chemotherapy is still poorly 
investigated but the majority of the studies did not allow 
simultaneous chemotherapy and recommended a chemotherapy-free 
interval of several weeks prior to and after SBRT. Clinical outcome of 
SBRT for pulmonary metastases is promising with toxicity grade >2 of 
<10%: radiation induced pneumonitis and chest wall pain were the 
most frequently observed toxicities. Local tumor control was 
consistently achieved in 80-90% of the patients. Despite the majority 
of the patients developed progressive systemic disease, long term 
overall survival was observed in a similar proportion of the patients as 
in the surgical series. Despite these promising results, a better 
understanding of how to select patients, which benefit most from this 
local treatment, is warranted. Additionally, the combination of SBRT 
with concurrent chemotherapy and targeted therapy is poorly 
investigated. Finally, endpoints other than overall survival like 
prolonging a chemotherapy-free interval with improved quality-of-live 
are worth to evaluate in future prospective trials. 
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Resection of pulmonary metastases is commonly performed in patients 
whose primary disease is controlled. Lung metastases from a primary 
extra pulmonary malignancy are often a manifestation of widespread 
dissemination; however, some patients have no other evidence of 
disease. The largest number of solitary metastases survivors had 
metastases primarily in the lung and/or liver. With innovations in 
molecular imaging and advances in molecular oncology, the stage is 
set to detect truly solitary metastases early.Then, aggressive 
treatment by surgical excision, stereotactic body radiosurgery, 
targeted chemotherapy, or immunotherapy could eradicate the lesion. 
A broader staging system is recommended to encompass a solitary 
metastasis(M1) and oligometastases (M2) as distinct from multiple 
metastases (M3). Even if nonresectional therapies such as radio 
frequency ablation and stereotactic body radiation therapy are being 
used in centers for patients with oligometastases to the lungs,  
extensive experience with pulmonary metastasectomy in a number of 
different cancers has confirmed that resection can substantially 
prolong survival and cure some patients. Based upon these 
observations, aggressive resection of isolated pulmonary metastases 
has become a widely accepted treatment for appropriately selected 
patients. In addition, technological improvements in radiological 
screening of pulmonary metastases and thoracoscopic resection are 
fundamentally altering the management of these patients and their 
surgery. Despite high resolution computed tomography scan and 
positron emission tomography-computed tomography remain the 
preferred imaging modalities for pulmonary metastases, the 
sensitivity of the technique is 100% for lesions larger than 1 cm, but it 
decreases according to the size of the metastases (<5 mm). Indeed, 
there is a real problem of missing small metastatic lesions in the 
video-assisted thoracic surgery approach; complete manual 
